Financial Performance - Net sales for Q1 2025 were 1,581.4million,adecreaseof664.5 million from 60.4millioninQ12024,withanadjustednetincomeof155.2 million[5] - Adjusted EBITDA was 269.5million,representinganadjustedEBITDAmarginof17.0269.5 million, down from 283.0millioninQ12024,reflectingamarginof16.81,581.4 million, a decline of 5.9% compared to 1,679.8millioninQ12024[30]−LaboratorySolutionssegmentreportednetsalesof1,065.0 million, down 8.0% year-over-year, while Bioscience Production segment saw a slight decline of 1.2% to 516.4million[33]−Adjustedearningspershare(EPS)forQ12025was0.23, slightly up from 0.22inQ12024[27]−OperatingincomeforQ12025was147.4 million, with an operating income margin of 9.3%, compared to 146.3millionand8.7109.3 million, while free cash flow was 82.1million[6]−FreecashflowforQ12025was82.1 million, compared to 106.9millioninQ12024[28]−Adjustednetleveragewas3.2xasofMarch31,2025[6]−AdjustednetleverageratioasofMarch31,2025,was3.2x,calculatedfromtotaldebtof4,126.9 million minus cash and cash equivalents of 315.7million[29]CostManagementInitiatives−Thecompanyistargeting400 million in gross run-rate savings by the end of 2027 as part of its cost transformation initiative[7] Segment Performance - The Lab Solutions segment experienced reduced demand, particularly in the Education and Government end market, due to recent policy changes[3] - The Bioscience Production segment continued to show growth and order book momentum in process ingredients and single-use solutions[3] - Adjusted Operating Income margin for the Laboratory Solutions segment was 13.1%[13] - Adjusted Operating Income margin for the Bioscience Production segment was 23.9%[13] Other Financial Charges - Capital expenditures for Q1 2025 were 28.0million,downfrom34.7 million in Q1 2024[21] - The company incurred $18.1 million in pension termination charges during Q1 2025, which were not present in Q1 2024[24]
Avantor(AVTR)2025-04-25 10:21